News Immunomedics wows ESMO with breast cancer data reveal Immunomedics has revealed the trial data that convinced Gilead to stage a
News Gilead pays $21bn for Immunomedics ahead of breast cancer tr... Gilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer blockbuster Trodelvy, days before survival data is due to be reveal
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
